← Browse by Condition
Medical Condition
neuroblastoma
Total Trials
14
Recruiting Now
14
Trial Phases
EARLY_Phase 1, Phase 1, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for neuroblastoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — neuroblastoma Clinical Trials
How many clinical trials are currently recruiting for neuroblastoma?
ClinicalMetric currently tracks 14 actively recruiting clinical trials for neuroblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neuroblastoma?
neuroblastoma research spans Phase 1 (5 trials), Phase 2 (6 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neuroblastoma clinical trial?
Eligibility criteria for neuroblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 5
Phase 2 6
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06684639 EARLY_Phase 1
Recruiting
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
Enrollment
30 pts
Location
China
Sponsor
The General Hospital of Wester...
NCT03294954 Phase 1
Recruiting
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
Enrollment
70 pts
Location
United States
Sponsor
Baylor College of Medicine
NCT05192980
Recruiting
SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours
Enrollment
600 pts
Location
Czechia, France, Nor...
Sponsor
Institut Curie
NCT05027386 Phase 1, Phase 2
Recruiting
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Enrollment
125 pts
Location
China
Sponsor
Sun Yat-sen University
NCT06395103 Phase 1, Phase 2
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Enrollment
90 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
NCT00588068
Recruiting
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Enrollment
2,070 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT03721068 Phase 1
Recruiting
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
Enrollment
18 pts
Location
United States
Sponsor
UNC Lineberger Comprehensive C...
NCT06540963 Phase 2
Recruiting
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Enrollment
98 pts
Location
United States
Sponsor
Giselle Sholler
NCT03050268
Recruiting
Familial Investigations of Childhood Cancer Predisposition
Enrollment
1,500 pts
Location
United States
Sponsor
St. Jude Children's Research H...
NCT06172296 Phase 3
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Enrollment
478 pts
Location
United States, Austr...
Sponsor
National Cancer Institute (NCI...
NCT06933394 Phase 2
Recruiting
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
Enrollment
92 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
NCT05826158
Recruiting
18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma
Enrollment
25 pts
Location
Denmark
Sponsor
Rigshospitalet, Denmark
NCT06450041 Phase 2
Recruiting
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Enrollment
62 pts
Location
United States
Sponsor
New Approaches to Neuroblastom...
NCT04903899 Phase 2
Recruiting
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Enrollment
24 pts
Location
Denmark, Lithuania, ...
Sponsor
Jakob Stenman
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology